Back to School: How biopharma can reboot drug development. Access exclusive analysis here
In a double-blind, Belgian Phase IIa trial in 21 patients aged 8-16, a 450 mg/day
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury